공고 • May 19
Biotika a.s., Annual General Meeting, Jun 17, 2026 Biotika a.s., Annual General Meeting, Jun 17, 2026, at 09:00 Central European Standard Time. Location: companys seat in slovenska lupca, Slovakia New Risk • Apr 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 70% per year over the past 5 years. Market cap is less than US$10m (€7.28m market cap, or US$8.57m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). New Risk • Sep 24
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Shares are highly illiquid. Revenue has declined by 28% over the past year. Market cap is less than US$10m (€4.90m market cap, or US$5.76m). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. 공고 • May 19
Biotika a.s., Annual General Meeting, Jun 18, 2025 Biotika a.s., Annual General Meeting, Jun 18, 2025, at 11:00 Central European Standard Time. Location: at the company`s registered office, in slovenska lupca., Slovakia New Risk • Feb 18
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €7.00m (US$7.32m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 55% per year over the past 5 years. Market cap is less than US$10m (€7.00m market cap, or US$7.32m). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. New Risk • Sep 13
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €7.00m (US$7.75m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 42% per year over the past 5 years. Market cap is less than US$10m (€7.00m market cap, or US$7.75m). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €17.00, the stock trades at a trailing P/E ratio of 32.2x. Average trailing P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 54% over the past three years. New Risk • May 02
New major risk - Revenue and earnings growth Earnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 44% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (€23.4m market cap, or US$25.0m). New Risk • Apr 30
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (€23.4m market cap, or US$25.1m). New Risk • Apr 26
New major risk - Revenue and earnings growth Earnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 44% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€24.6m market cap, or US$26.4m). New Risk • Nov 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 42% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (€21.6m market cap, or US$23.1m). Board Change • Oct 21
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Head of Sales & Member of Supervisory Board Jozefína Gregová was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Aug 31
Investor sentiment deteriorated over the past week After last week's 20% share price decline to €24.00, the stock trades at a trailing P/E ratio of 58.2x. Average trailing P/E is 20x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 5.0% over the past three years. Board Change • Aug 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Head of Sales & Member of Supervisory Board Jozefína Gregová was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • May 09
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Head of Sales & Member of Supervisory Board Jozefína Gregová was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 25
Full year 2020 earnings released The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: €19.3m (down 27% from FY 2019). Net income: €2.28m (up 13% from FY 2019). Profit margin: 12% (up from 7.7% in FY 2019). The increase in margin was driven by lower expenses. Valuation Update With 7 Day Price Move • Mar 08
Investor sentiment improved over the past week After last week's 15% share price gain to €40.60, the stock is trading at a trailing P/E ratio of 10.8x, up from the previous P/E ratio of 9.4x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 55%.